GlassScriptPhysician profile
Daniel Thomas Miles
NPI 1841648094
$2,214.94
in general payments reported to CMS, 2019-2025
26 companies · $1,600 in 2025
The $1,600 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.17 · 2023: $69.64 · 2024: $531 · 2025: $1,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,175 · Education: $25.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,174.82 |
| Education | $25.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $353.02 | 2023-2025 | Imfinzi, Enhertu, Lynparza |
| Daiichi Sankyo INC. | $346.32 | 2024-2025 | Enhertu, Datroway |
| Pfizer INC. | $262.74 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $249.46 | 2024-2025 | |
| Glaxosmithkline, LLC. | $152.36 | 2024-2025 | Ojjaara, Blenrep, Jemperli |
| Merck Sharp & Dohme LLC | $114.28 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Eisai INC. | $113.41 | 2024-2025 | |
| Tempus Ai, INC | $92.83 | 2025 | Xt Cdx |
| E.R. Squibb & Sons, L.L.C. | $78.02 | 2022-2025 | Opdivo, Opdualag |
| Abbvie INC. | $74.08 | 2024-2025 | |
| Genzyme Corporation | $44.45 | 2025 | |
| Stryker Corporation | $40.11 | 2024 | Aequalis Ascend Flex |
| Janssen Biotech, INC. | $35.09 | 2024-2025 | Talvey, Darzalex, Tecvayli |
| Exelixis INC. | $31.84 | 2025 | Cabometyx |
| Astellas Pharma US INC | $31.65 | 2024-2025 | Vyloy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $22.76 | 2024-2025 | Mektovi, Lorbrena, Braftovi |
| Sobi, INC | $21.48 | 2025 | |
| Servier Pharmaceuticals LLC | $21.37 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.87 | 2025 | |
| Emd Serono, INC. | $18.83 | 2025 | |
| Stemline Therapeutics INC. | $17.99 | 2024 | Orserdu |
| Lilly USA, LLC | $17.76 | 2024 | Retevmo, Jaypirca |
| Incyte Corporation | $16.59 | 2025 | Monjuvi |
| Gilead Sciences, INC. | $15.50 | 2025 | Trodelvy |
| Celgene Corporation | $15.35 | 2025 | Reblozyl |
| Iovance Biotherapeutics, INC. | $7.78 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Miles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.